NAD+: a complete guide to the anti-aging coenzyme

Nicotinamide adenine dinucleotide. That's the full name, and the "+" denotes its oxidized form. It's a coenzyme, meaning it doesn't act alone. It partners with enzymes to make their reactions possible. NAD+ sits at the center of two distinct kinds of cellular work.

The first is energy metabolism. Every major pathway that turns food into ATP, glycolysis, the TCA cycle, fatty acid oxidation, oxidative phosphorylation, relies on NAD+ accepting and donating electrons as it cycles between NAD+ and NADH. Without it, mitochondria stop. Cells die. This part is not controversial; it's textbook biochemistry going back decades.

The second role is newer and more interesting. NAD+ is also consumed, irreversibly used up, as a cosubstrate by enzymes that regulate gene expression, repair DNA, and modulate immune signaling. That consumption pool is small relative to total NAD+, but it appears to be the part that matters most for aging biology.

A simple way to hold this: NAD+ is both the fuel gauge and one of the regulatory levers inside the cell. When it drops, both functions degrade at once.

Three enzyme families consume NAD+. Each tells you something about why its levels matter.

Sirtuins (SIRT1 through SIRT7) are NAD+-dependent deacylases. They strip chemical tags off proteins, and in doing so they regulate mitochondrial biogenesis, DNA repair signaling, and metabolic homeostasis. SIRT1 and SIRT3 are the ones aging researchers care about most. Crucially, sirtuin activity tracks intracellular NAD+ availability in real time. When NAD+ falls, sirtuins quiet down. This is the mechanistic link that connects "your NAD+ levels are lower at 65 than at 25" to "your cells regulate themselves less well at 65 than at 25."

PARPs are poly-ADP-ribose polymerases. Their job is DNA damage response, and they're expensive: a single round of PARP activity consumes a lot of NAD+. In a young cell with low background damage, this is fine. In an older cell accumulating DNA breaks from decades of oxidative stress, PARPs run hard and drain the NAD+ pool. That drain then starves the sirtuins. The cycle reinforces itself.

CD38, an ectoenzyme on the surface of immune cells, hydrolyzes NAD+ as part of calcium signaling. CD38 expression climbs with age, particularly in the setting of chronic low-grade inflammation, what some researchers call inflammaging. More CD38, less NAD+.

So you have three taps draining the same tank, and at least two of them open further as you age.

Tissue NAD+ falls measurably with age in human liver, skin, brain, plasma, skeletal muscle, and macrophages ^[1]. The decline isn't subtle. By one set of measurements, levels in some tissues drop substantially between young adulthood and old age.

Two mechanisms drive the loss. On the production side, the salvage pathway, the cell's main route for recycling nicotinamide back into NAD+, slows down. The rate-limiting enzyme, NAMPT, becomes less active ^[2]. On the consumption side, both PARP and CD38 ramp up for the reasons above: more DNA damage, more inflammation, more taps open.

That said, "NAD+ declines with age" is a population-level statement built from cross-sectional studies. Individual variation is large. Whether the decline is a cause of aging, a consequence of it, or both, and which tissues matter most, remains a live research question.

You can't take NAD+ as a pill and have it enter cells intact. The molecule is too large and too charged to cross membranes meaningfully. So supplementation works through precursors that the cell then assembles into NAD+ on the inside.

Nicotinamide riboside (NR). Phosphorylated inside the cell into NMN, then into NAD+. The most clinically studied oral precursor. Marketed under several brand names, most prominently NIAGEN.

Nicotinamide mononucleotide (NMN). One step closer to NAD+ structurally; it gets adenylated into NAD+ by NMNAT enzymes. Whether being "one step closer" matters in practice is exactly the question recent trials have tried to answer.

Nicotinamide (Nam). Cheap, abundant, and the form your body produces during normal NAD+ turnover. In controlled human trials it doesn't appear to sustain elevated blood NAD+ the way NR and NMN do.

Niacin / nicotinic acid (NA). The original B3. Raises NAD+ via the Preiss-Handler pathway. Cheap and effective at raising levels, but causes the well-known flushing response and, at sustained high doses, carries its own hepatotoxicity profile.

Tryptophan. Your body can synthesize NAD+ from the amino acid tryptophan via the kynurenine pathway. Low efficiency, but it's how a meaningful share of basal NAD+ gets made.

One genuinely interesting wrinkle: a 2024 Nestlé-led trial proposed that both NR and NMN may actually be metabolized by gut microbiota into nicotinic acid before entering circulation ^[3]. If that's right, the elegant intracellular pathway story on the supplement bottle is partially fiction. The active path runs through your microbiome.

This is where the wellness industry and the data diverge most sharply.

The IV NAD+ pitch is intuitive. Skip the gut, skip the metabolism, deliver the molecule directly. Higher levels, faster. The problem is that NAD+ doesn't enter cells intact, so what an IV infusion actually does is flood the extracellular space with concentrations far above any physiological range, and then rely on the molecule being broken down and resynthesized to do anything useful.

In June 2026, a research group at Restore Hyper Wellness published the first real tolerability comparison of IV NAD+ against IV NR in Frontiers in Aging ^[4]. The findings were striking. The majority of participants receiving IV NAD+ reported moderate-to-severe adverse effects: abdominal cramping, nausea, vomiting, tachycardia, chest pressure, throat pain. All of it ceased the moment the infusion ended, which fits a model in which extracellular NAD+ is acutely activating purinergic signaling receptors rather than doing anything mitochondrial.

IV NR, in the same study, was substantially better tolerated. Infusions completed considerably faster. Side effects were mild and transient. Liver enzymes stayed stable in both groups.

100% adverse event rate. That's not a number you see often in tolerability work.

For oral supplementation, the comparison is more boring and more reassuring. NR and NMN, dosed at one gram daily for several weeks in a Nestlé-sponsored trial, both raised whole-blood NAD+ roughly two-fold over placebo. The increments were comparable, with both NR and NMN producing similar increases in blood NAD+ levels. Nicotinamide didn't sustain an effect. Side effects across oral precursor trials have been mild, with occasional nausea, fatigue, headache, and mild GI upset.

The honest read: oral precursors raise blood NAD+ reliably and without much drama. IV NAD+ raises blood NAD+ too, but the route comes with a side-effect profile that nobody pushing the drip discusses in their marketing copy.

The clinical trial landscape for NAD+ precursors is larger than it was five years ago and still smaller than the marketing suggests. Most trials have been short, weeks rather than years. Most have measured biomarkers, not outcomes. None has yet measured what people actually want to know, which is whether long-term supplementation extends healthspan or lifespan in humans.

Here's what the better-designed work shows.

Yoshino and colleagues, publishing in Science in 2021, found that NMN supplementation increased muscle insulin sensitivity in postmenopausal prediabetic women ^[5]. Real effect, mechanistically plausible, small sample.

Dollerup and colleagues, working in obese men, found that NR was safe and well tolerated, but did not improve insulin sensitivity, did not improve lipid mobilization, and in a follow-up study did not alter mitochondrial respiration, content, or morphology in skeletal muscle ^[6]. Three trials, mostly null results, in the population you'd most expect to benefit.

Remie and colleagues reported NR-induced changes in body composition and skeletal muscle acetylcarnitine in obese adults ^[7]. Modest. A pilot in heart failure patients with left ventricular assist devices (NCT03727646) tested NR at high daily doses for safety; it was tolerated. Orr and colleagues published a 2024 RCT of NR in older adults with mild cognitive impairment in GeroScience ^[8]. Inflammatory cytokine markers have come down in small studies of older men after a few weeks of supplementation.

Pull back and what you have is a body of evidence that's consistent on a few points: precursors raise NAD+, they appear safe in the short term, and they sometimes move biomarkers in the direction you'd want. Beyond that, the picture is mixed. A recent systematic review of RCTs concluded, politely, that clinical efficacy for hard endpoints in humans remains incompletely established.

Translated: nobody has shown, in humans, that taking NAD+ precursors makes you live longer or get sick less.

Metabolic health. The strongest signal. NMN improved insulin sensitivity in one well-conducted Science paper in postmenopausal prediabetic women. Other metabolic trials have been null. If there's a population most likely to benefit, current data points toward older women with early metabolic dysfunction, not healthy 30-year-olds optimizing.

Neurodegeneration. Mechanistic plausibility is real. Sirtuins regulate neuronal stress response; PARP overactivation contributes to neurodegeneration. The Orr 2024 trial in mild cognitive impairment is the most rigorous human work to date. It's one trial. Larger and longer studies are running.

Cardiovascular function. Small studies have shown trends toward improved systolic blood pressure and aortic stiffness with NAD+ precursors. The LVAD pilot established short-term safety in a fragile cardiac population. Nothing yet on hard endpoints like heart attack or mortality.

DNA repair. Mechanistically central. PARPs need NAD+ to do their job. Whether boosting NAD+ improves repair capacity in healthy humans in ways that translate to disease reduction is the trillion-dollar question, and no one has answered it.

A note worth flagging: NAD+ also fuels cancer cell metabolism. Tumors need it like healthy cells do, sometimes more. The net effect of long-term NAD+ elevation on cancer risk in humans is genuinely uncharacterized. This is one of the open questions that should give anyone pause before committing to a decades-long high-dose protocol.

Oral NR and NMN. Across multiple RCTs, side effects are uncommon and mild: occasional nausea, mild flushing, fatigue, headache, mild diarrhea. Most participants in most trials report nothing notable. Liver enzymes generally stable. The systematic reviews are broadly reassuring on short-term safety. Long-term safety, meaning years rather than weeks, has not been studied in any rigorous way.

IV NAD+. Not reassuring. The Reyna 2026 tolerability work documented moderate-to-severe acute symptoms in every participant: cramping, nausea, vomiting, tachycardia, chest pressure. Symptoms resolved when infusion stopped, which is the one piece of good news. No serious long-term events reported, but the population studied is small and follow-up short.

FAERS data. The FDA's adverse event reporting system shows reports tied to nicotinamide and related B3 compounds, including anemia and nausea, but the data doesn't cleanly separate NMN and NR from older nicotinic acid use, which has its own and worse side-effect profile. Treat FAERS numbers with caution here.

Higher-risk populations for IV administration. First-time recipients, anyone with cardiovascular disease, anyone with real liver or kidney impairment, pregnant or breastfeeding women. The drip is not the same risk profile as the pill.

The regulatory story turned twice in three years, which is itself a signal of how unsettled this category is.

In November 2022, the FDA declared NMN excluded from the definition of a dietary supplement, citing a pending Investigational New Drug application by MetroBiotech ^[9]. Under the drug preclusion clause, if a substance gets investigated as a drug before being marketed as a supplement, it can't go back to being a supplement.

Then, on September 29, 2025, the FDA reversed ^[10]. In two letters, the agency concluded NMN had in fact been marketed as a supplement in the US before the IND was authorized. The race to market ran the other way. NMN is now lawful as a dietary supplement ingredient again. A New Dietary Ingredient Notification is still technically required, and patent disputes between manufacturers remain unresolved.

NR has been on cleaner ground throughout. The patented NIAGEN form is GRAS-affirmed, FDA-notified, and authorized by global regulators ^[11]. Not approved as a drug, but well established as a supplement.

NAD+ itself, given by IV in wellness clinics, sits in an actual grey zone. Not FDA-approved as a drug. Not categorized as a dietary supplement in that route of administration. It exists because clinicians can administer substances under their own discretion, and because the wellness industry has built a business around it. There's no FDA-approved indication for IV NAD+. There's no standardized protocol. There's no specific regulatory oversight of dose, rate, or quality control.

Quality control matters here. An analysis of numerous NMN brands found that most failed to meet their label claims. For readers considering supplementation, the brand and the COA matter as much as the molecule.

The honest candidate profile is narrower than the marketing suggests.

Most likely to benefit from oral precursors based on current data: older adults with documented metabolic dysfunction, particularly postmenopausal women with insulin resistance or prediabetes. The Yoshino 2021 trial is the strongest positive signal in the literature, and the population it studied matters.

Possibly worth considering, based on plausibility but thin direct evidence: older adults with subjective cognitive complaints, people with chronic inflammation, those recovering from large physiological stress. None of this is established. All of it's reasonable to discuss with a clinician.

Probably won't see meaningful benefit: healthy adults under 40 with no metabolic dysfunction. NAD+ levels in this group are already high. The biomarker movements in trials of healthy young adults have been modest at best.

Should be cautious: anyone with active or recent cancer, given the uncharacterized effect of NAD+ elevation on tumor metabolism. Anyone considering IV NAD+ for the first time, given the acute side-effect profile. Anyone making decisions based on a single trial or a charismatic podcast appearance.

The biggest mismatch in this category isn't between the science and the supplement. It's between what the science can support and what's being sold. Oral NR and NMN are reasonable interventions with modest, real effects on a narrow set of biomarkers. IV NAD+ is a high-side-effect intervention with no proven advantage over oral precursors and a regulatory status that's best described as "permitted because no one has stopped it."

What's solid: NAD+ is central to cellular energy and signaling. Levels decline with age in humans across multiple tissues. Oral NR and NMN raise blood NAD+ reliably in controlled trials. Short-term safety of oral precursors is well established. NMN's regulatory status, after the September 2025 FDA reversal, is back to "lawful supplement."

What's plausible but unproven in humans: meaningful improvements in metabolic, cognitive, cardiovascular, or longevity outcomes from sustained supplementation. Animal data is impressive. Mechanistic logic is strong. The human trials so far are short, small, and mostly biomarker-focused.

What's actively concerning: IV NAD+ tolerability, the lack of long-term safety data at high doses, the uncharacterized cancer-risk question, and the gap between marketing claims and trial outcomes.

Open questions worth tracking: whether the NR-and-NMN-to-nicotinic-acid microbiome pathway changes how we should dose. Whether longer, larger trials with hard endpoints will move the field. Whether the regulatory status of NMN holds. Whether IV NR, which looks markedly better tolerated than IV NAD+ in the one good comparison we have, becomes the better-validated infusion option.

For now, the data supports a measured stance: oral precursors are reasonable for a narrow set of candidates, the evidence is improving but thin, and the longevity narrative remains a hypothesis dressed in better marketing than it has earned.